Amarin Corp Plc (AMRN)

[KCSVEN]

During the three months ended March 31, 2013, net cash decreased by approximately $58.4 million, including approximately $32.0 million paid for sales and marketing related expenses in connection with the initial commercial launch of Vascepa, approximately $13.0 million paid in support of the REDUCE-IT cardiovascular outcomes study and approximately $11.8 million for Vascepa API purchased in connection with the buildup of our commercial supply and for clinical trial material. During the three months ended March 31, 2013, research and development expense included $3.0 million for API from suppliers which were not approved until April 2013 which, for accounting purposes, was expensed in the period received.

Amarin reported cash and cash equivalents of $201.8 million at March 31, 2013.

Cash burn should moderate after launch and with increased sales.

If not for Anchor launch will not need money but will need money to launch Anchor as expected.

As always comes down to Anchor and how they partner